Concept & Business Plan
CardioVision™ is an infarct-avid radiopharmaceutical imaging agent that localizes specifically in damaged cardiac cells (myocardial infarction). It should be used in a time window of 6 days after any myocardial infarction, in order to allow any future therapy, including the Stem Cell Therapy for heart tissue regeneration.
The Business Plan covers:
Introduction - The Company - The Products -
The Market -Risk Assesment - Finance - Time Frame
Attachments to the Business Plan covers:
Corporate Background, Key Personnel, Present Ownership of Erfa Biotech,
CardioVision Concept, Monoclonal Antibody Production, Heart Ischemia -
Medical Background, Scar Tissue after Myocardial Infarction, Yearly Recurrent
Total MI Population, Ischemic Heart Disease - USA & European Epidemiological
Data, Prevalence of CardioVascular Diseases in USA, Disease Progression
in Patients with CHD, Prognostic use of CardioVision™, Heart Attack
Management, Principle of Stem Cells Transplantation, Financial Analysis:
Expected Revenue, Profit and Loss Statement, Fixed Overhead and Clinical
Development Expenses, Description of Marketed Monoclonal Antibodies, Glossary
of Medical Abbreviations and References.
Available upon request. Confidentiality agreement mandatory.
 |
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
|
||||
 |
 |
 |
 |
 |
|
||||
 |
|
||||||||